Long-term donor-specific tolerance in rat cardiac allografts by intrabone marrow injection of donor bone marrow cells

Transplantation

Volumn 85, Issue 1, 2008, Pages 93-101

  Guo, Kequan ^a,b   Inaba, Muneo ^a   Li, Ming ^a   An, Jun ^c   Cui, Wenhao ^a   Song, Changye ^a   Wang, Jianfeng ^a   Cui, Yunze ^a   Sakaguchi, Yutaku ^a   Tsuda, Masanobu ^a   Omae, Mariko ^a   Ando, Yugo ^a   Li, Qing ^a   Wang, Xiaoli ^a   Feng, Wei ^a   Ikehara, Susumu ^a  

^a KANSAI MEDICAL UNIVERSITY   (Japan)

^b QINGDAO UNIVERSITY   (China)

^c JILIN UNIVERSITY   (China)

Author keywords

Bone marrow transplantation; Heart transplantation; Intrabone marrow injection; Tolerance induction

Indexed keywords

FLUDARABINE PHOSPHATE;

ALLOGRAFT; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BONE MARROW CELL; BONE MARROW TRANSPLANTATION; CHIMERA; CONTROLLED STUDY; GRAFT SURVIVAL; HEART GRAFT; HEART TRANSPLANTATION; LOW ENERGY RADIATION; NONHUMAN; PRIORITY JOURNAL; RADIATION DOSE; RAT;

ANIMALS; ANTINEOPLASTIC AGENTS; BONE MARROW TRANSPLANTATION; CHIMERISM; DOSE-RESPONSE RELATIONSHIP, RADIATION; GRAFT SURVIVAL; HEART TRANSPLANTATION; INJECTIONS; RATS; RATS, INBRED BN; RATS, INBRED F344; TIME FACTORS; TRANSPLANTATION TOLERANCE; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME; VIDARABINE;

EID: 38149067599     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.tp.0000296061.71662.76     Document Type: Article

References (37)

1. Pham SM, Kormos RL, Hattler BG, et al. A prospective trial of tacrolimus (FK506) in clinical heart transplantation: Intermediate-term results. J Thorac Cardiovasc Surg 1996; 111: 764.
2. Ildstad ST, Sachs DH. Reconstitution with syngeneic plus allogeneic or xenogeneic bone marrow leads to specific acceptance of allografts or xenografts. Nature 1984; 307: 168.
3. Kawai T, Cosimi AB, Colvin RB, et al. Mixed allogeneic chimerism and renal allograft tolerance in cynomolgus monkeys. Transplantation 1995; 59: 256.
4. Buhler LH, Spitzer TR, Sykes M, et al. Induction of kidney allograft tolerance after transient lymphohematopoietic chimerism in patients with multiple myeloma and end-stage renal disease. Transplantation 2002; 74: 1405.
5. Gandy KL. Tolerance induction for solid organ grafts with donor-derived hematopoietic reconstitution. Immunol Res 2000; 22: 147.
6. Cobbold SP, Martin G, Qin S, et al. Monoclonal antibodies to promote marrow engraftment and tissue graft tolerance. Nature 1986; 323: 164.
7. Sykes M, Szot GL, Swenson KA, et al. Induction of high levels of allogeneic hematopoietic reconstitution and donor-specific tolerance without myelosuppressive conditioning. Nat Med 1997; 3: 783.
8. Wekerle T, Kurtz J, Ito H, et al. Allogeneic bone marrow transplantation with co-stimulatory blockade induces macrochimerism and tolerance without cytoreductive host treatment. Nat Med 2000; 6: 464.
9. Seung E, Mordes JP, Rossini AA, et al. Hematopoietic chimerism and central tolerance created by peripheral-tolerance induction without myeloablative conditioning. J Clin Invest 2003; 112: 795.
10. Kushida T, Inaba M, Hisha H, et al. Intrabone marrow injection of allogeneic bone marrow cells: A powerful new strategy for treatment of intractable autoimmune diseases in MRL/lpr mice. Blood 2001; 97: 3292.
11. Nakamura K, Inaba M, Sugiura K, et al. Enhancement of allogeneic hematopoietic stem cell engraftment and prevention of GvHD by intrabone marrow transplantation plus donor lymphocyte infusion. Stem Cells 2004; 22: 125.
12. Esumi T, Inaba M, Ichioka N, et al. Successful allogeneic leg transplantation in rats in conjunction with intrabone marrow injection of donor bone marrow cells. Transplantation 2003; 76: 1543.
13. Kaneda H, Adachi Y, Saito Y, et al. Long-term observation after simultaneous lung and intrabone marrow-bone marrow transplantation. J Heart Lung Transplant 2005; 24: 1415.
14. Taira M, Inaba M, Takada K, et al. Treatment of streptozotocin-induced diabetes mellitus in rats by transplantation of islet cells from two major histocompatibility complex disparate rats in combination with intra bone marrow injection of allogeneic bone marrow cells. Transplantation 2005; 79: 680.
15. Plunkett W, Huang P, Gandhi V. Metabolism and action of fludarabine phosphate. Semin Oncol 1990; 17: 3.
16. Chun HG, Leyland-Jones B, Cheson BD. Fludarabine phosphate: A synthesis purine antimetabolite with significant activity against lymphoid malignancies. J Clin Oncol 1991; 9: 175.
17. Goodman ER, Fiedor PS, Fein S, et al. Fludarabine phosphate: A DNA synthesis inhibitor with potent immunosuppressive activity and minimal clinical toxicity. Am Surg 1996; 62: 435.
18. Tomita Y, Zhang QW, Yoshikawa M, et al. Improved technique of heterotopic cervical heart transplantation in mice. Transplantation 1997; 64: 1598.
19. Martin PJ. Determinants of engraftment after allogeneic marrow transplantation. Blood 1992; 79: 1647.
20. Hashimoto F, Sugiura K, Inoue K, et al. Major histocompatibility complex restriction between hematopoietic stem cells and stromal cells in vivo. Blood 1997; 89: 49.
21. Wang J, Kimura T, Asada R, et al. SCID-repopulating cell activity of human cord blood-derived CD34- cells assured by intrabone marrow injection. Blood 2003; 101: 2924.
22. Rifle G, Mousson C. Donor-derived hematopoietic cells in organ transplantation: A major step toward allograft tolerance? Transplantation 2003; 75: 3S.
23. Starzl TE, Demetris AJ, Murase N, et al. Cell migration, chimerism, and graft acceptance. Lancet 1992; 339: 1579.
24. Manaco AP. Prospects and strategies for clinical tolerance. Transplant Proc 2004; 36: 227.
25. Schlitt HJ, Hundrieser J, Ringe B, et al. Donor-type microchimerism associated with graft rejection eight years after liver transplantation. N Engl J Med 1994; 330: 646.
26. Moraes de LV, Bueno V, Panajotopoulos N, et al. Microchimerism does not correlate with survival of murine cardiac allografts. Transplant Proc 2004; 36: 1021.
27. Metzler B, Gfeller P, Bigaud M, et al. Combinations of antiLFA-1, everolimus, antiCD40 ligand, and allogeneic bone marrow induce central transplantation tolerance through hemopoietic chimerism, including protection from chronic heart allograft rejection. J Immunol 2004; 173: 7025.
28. Tomita Y, Khan A, Sykes M. Role of intrathymic clonal deletion and peripheral anergy in transplantation tolerance induced by bone marrow transplantation in mice conditioned with a nonmyeloablative regimen. J Immunol 1994; 153: 1087.
29. Guo Z, Wu T, Sozen H, et al. A substantial level of donor hematopoietic chimerism is required to protect donor-specific islet grafts in diabetic NOD mice. Transplantation 2003; 75: 909.
30. Hosenpud JD, Bennett LE, Keck BM, et al. The registry of the international society for heart and lung transplantation: Eighteenth official report-2001. J Heart Lung Transplant 2001; 20: 805.
31. Waller J, Brook NR, Nicholson ML, et al. Cardiac allograft vasculopathy: current concepts and treatment. Transpl Int 2003; 16: 367.
32. Weis M, von Scheidt W. Coronary artery disease in the transplanted heart. Annu Rev Med 2000; 51: 81.
33. Ash RC, Casper JT, Chitambar CR, et al. Successful allogeneic transplantation of T-cell-depleted bone marrow from closely HLA-matched unrelated donors. N Engl J Med 1990; 322: 485.
34. Takeuchi K, Inaba M, Miyashima S, et al. A new strategy for treatment of autoimmune diseases in chimeric resistant MRL/lpr mice. Blood 1998; 91: 4616.
35. Martin PJ. Donor CD8 cells prevent allogeneic marrow graft rejection in mice: Potential implications for marrow transplantation in humans. J Exp Med 1993; 178: 703.
36. Tomita Y, Mayumi H, Eto M, et al. Importance of suppressor T cells in cyclophosphamide-induced tolerance to the nonH-2 encoded antigens. J Immunol 1990; 144: 463.
37. Asiedu C, Meng Y, Wang W, et al. Immunoregulatory role of CD8α in the effect. Transplantation 1999; 67: 372.